MANGOCEUTICALS INC

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

MGRX$0.20+1.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

Mangoceuticals, Inc.

Balance Sheets

	December 31, 2023	December 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$739,006	$682,860
Inventory	18,501	-
Prepaid expenses - related party	60,953	11,745
TOTAL CURRENT ASSETS	818,460	694,605
FIXED ASSETS
Property and equipment, net of accumulated depreciation of $28,752 and $3,863	96,129	117,499
TOTAL FIXED ASSETS	96,129	117,499
OTHER ASSETS
Deposits	16,942	16,942
Right of use - asset	119,262	174,241
TOTAL OTHER ASSETS	136,204	191,183
TOTAL ASSETS	$1,050,793	$1,003,287
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable and accrued liabilities	$140,765	$33,675
Payroll tax liabilities	6,595	2,717
Notes payable to related parties	-	89,200
Notes payable	-	78,260
Right-of-use liability - operating lease	63,718	56,725
TOTAL CURRENT LIABILITIES	211,078	260,577
LONG-TERM LIABILITIES
Right-of-use liability - operating lease	64,961	128,680
TOTAL LONG-TERM LIABILITIES	64,961	128,680
TOTAL LIABILITIES	276,039	389,257
COMMITMENTS AND CONTINGENCIES (SEE NOTE 10)	-	-
STOCKHOLDERS’ EQUITY
Common stock (par value $0.0001, 200,000,000 shares authorized, of which 21,419,500 and 13,365,000 shares issued and outstanding as of December 31, 2023 and 2022, respectively)	2,142	1,337
Additional paid in capital	12,000,785	2,628,449
Accumulated deficit	(11,228,173)	(2,015,756)
TOTAL STOCKHOLDERS’ EQUITY	774,754	614,030
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$1,050,793	$1,003,287

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.